UNASSIGNED: We investigated the effect of @entity136 ( @entity14113 ), a key drug for @entity788 treatment, on the expression of cell surface @entity1531 /B in @entity788 cells and resulting @entity137 of y   T cells. We assessed the effect of @entity14113 on the upregulation of cell surface @entity1531 /B expression by flow cytometry, utilizing six @entity788 cell lines. @entity1531 and @entity4071 expressions from resected @entity788 @entity1 specimens, which received neoadjuvant chemotherapy (NAC) with @entity14113 , were analyzed by immunohistochemistry. @entity14113 could increase @entity1531 /B expression on cell surface in @entity788 cell lines (in 2 of 6 cell lines). This effect was most effectively at concentration not affecting cell growth of @entity14113 (0.001   M), because @entity1531 /B negative population was appeared at concentration at cytostatic and cytotoxic effect to cell growth (0.1 and 10   M). The cytotoxic activity of y   T cells against PANC-1 was detected and functions through interactions between @entity3223 and @entity1531 /B. However, the enhancement of @entity3223 -dependent @entity137 with increased @entity1531 /B expression, by @entity14113 treatment, was not observed. In addition, soluble MIC molecules were released from @entity788 cell lines in culture supernatant with @entity14113 treatment. Immunohistochemical staining demonstrated that @entity1531 expression in @entity5 cells and @entity4071 positive cells surrounding @entity5 were significantly higher in the NAC group compared to that of the control group. There was a significant correlation between NAC and @entity1531 expression, as well as NAC and @entity4071 positive cell expression. The present results indicate that low-dose @entity14113 -induced @entity1531 /B expression enhances innate immune function rather than @entity137 in @entity788 . In addition, our result suggests that the inhibition of cleavage and release of MIC molecules from the @entity5 surface could potentially improve @entity3223 -dependent @entity137 .

Low-dose @entity136 induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in XXXX .

@entity1 :: ('9606', 'Species') :: ['patient'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic cancer'] @entity137 :: ('MESH:D064420', 'Disease') :: ['cytotoxicity'] @entity3223 :: ('22914', 'Gene') :: ['NKG2D'] @entity1531 :: ('100507436', 'Gene') :: ['MICA'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity14113 :: ('C056507', 'Chemical') :: ['GEM'] @entity4071 :: ('2214', 'Gene') :: ['CD16'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']
@entity788 :: (MESH:D010190,Disease) :: ['pancreatic cancer']
